Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.60 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 6/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.41 |
| ▸ | MYC | P01106 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10622006 | 0.77 | GBA1 (0.62) | GBA1AOC3HCAR3MYCALDH1A1 | |
| SCHEMBL179288 | 0.77 | GBA1 (0.62) | GBA1AOC3HCAR3MYCKMT2A | |
| SCHEMBL856704 | 0.76 | GBA1 (0.56) | GBA1AOC3HCAR3MYC | |
| SCHEMBL4934216 | 0.76 | APP (0.47) | ESR1ESR2 | |
| SCHEMBL1432871 | 0.75 | GBA1 (0.60) | GBA1AOC3HCAR3MYCKMT2A | |
| SCHEMBL2793295 | 0.75 | GBA1 (0.60) | GBA1AOC3HCAR3MYCALDH1A1 | |
| SCHEMBL8430068 | 0.75 | GBA1 (0.60) | GBA1AOC3HCAR3MYC | |
| SCHEMBL30175373 | 0.75 | GBA1 (0.60) | GBA1AOC3HCAR3MYC | |
| SCHEMBL4734183 | 0.75 | GBA1 (0.60) | GBA1AOC3HCAR3MYCKMT2A | |
| SCHEMBL17274025 | 0.75 | GBA1 (0.60) | GBA1AOC3HCAR3MYCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1268486-A2 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074823-A2 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TST, STS, AHR | GBA1 3586/4885AOC3 2076/4885HCAR3 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.